Watch REGN. Know when insiders buy.
One email the day a filing lands. Free.
Work order
63
WATCH · insiders 25, shorts 100
Insiders, 90 days
−$2.3M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
5 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $77.8BP/E 20.5DIV YIELD 0.44%FCF YIELD 4.84%REV TTM $15.5B +9.3%NET INCOME $4.3B −2.9%NET CASH $469.2M52W 555.51 – 852.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $4.3B | +16.7% | — | $1.3B | $1.3B | −6.8% | 12.23 | $813M | $240.2M | $572.8M | Jul 30 |
| Q1 2026 · Mar 31 | $3.6B | +19.0% | — | $642.9M | $727.2M | −10.1% | 6.75 | $1.1B | $230.6M | $848.3M | Jul 30 |
| Q4 2025 · Dec 31 | $3.9B | +2.5% | — | $879.9M | $844.6M | −8.0% | 7.87 | $1.2B | $248.7M | $922M | Feb 4 |
| Q3 2025 · Sep 30 | $3.8B | +0.9% | — | $1B | $1.5B | +8.9% | 13.62 | $1.6B | $201.4M | $1.4B | Feb 4 |
| Q2 2025 · Jun 30 | $3.7B | +3.6% | — | $1.1B | $1.4B | −2.8% | 12.81 | $1.1B | $219M | $925.4M | Jul 30 |
| Q1 2025 · Mar 31 | $3B | −3.7% | — | $591.7M | $808.7M | +12.0% | 7.27 | $1B | $229.3M | $815.8M | Jul 30 |
| Q4 2024 · Dec 31derived | $3.8B | +10.3% | — | $990.2M | $917.7M | −20.9% | 8.11 | $1.3B | $199.6M | $1.1B | Feb 4 |
| Q3 2024 · Sep 30 | $3.7B | +10.6% | — | $1.2B | $1.3B | +33.0% | 11.54 | $1.3B | $241.9M | $1B | Oct 28 |
| Q2 2024 · Jun 30 | $3.5B | — | — | $1.1B | $1.4B | — | 12.41 | $354M | $180.5M | $173.5M | Oct 28 |
| Q1 2024 · Mar 31 | $3.1B | — | — | $751.4M | $722M | — | 6.27 | $1.5B | $133.9M | $1.4B | Oct 28 |
| Q4 2023 · Dec 31derived | $3.4B | — | — | $972.9M | $1.2B | — | 10.20 | $1.1B | $251.4M | $838.3M | Feb 4 |
| Q3 2023 · Sep 30 | $3.4B | — | — | $1.1B | $1B | — | 8.89 | $1.1B | $176M | $938.3M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $14.3B | — | $3.6B | $4.5B | 31.4% | 41.48 | $5B | $898.4M | $4.1B | $3.4B | $370.3M |
| FY2024 · to Dec 31 | $14.2B | — | $4B | $4.4B | 31.1% | 38.34 | $4.4B | $755.9M | $3.7B | $2.6B | $0 |
| FY2023 · to Dec 31 | $13.1B | — | $4B | $4B | 30.1% | 34.77 | $4.6B | $718.6M | $3.9B | $2.2B | $0 |
| FY2022 · to Dec 31 | $12.2B | — | $4.7B | $4.3B | 35.6% | 38.22 | $5B | $590.1M | $4.4B | $2.1B | — |
| FY2021 · to Dec 31 | $16.1B | — | $8.9B | $8.1B | 50.2% | 71.97 | $7.1B | $551.9M | $6.5B | $1.6B | — |
| FY2020 · to Dec 31 | $8.5B | — | $3.6B | $3.5B | 41.3% | 30.52 | $2.6B | $614.6M | $2B | $5.8B | — |
Every number comes from REGENERON PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.